home / stock / capr / capr news


CAPR News and Press, Capricor Therapeutics Inc. From 02/20/24

Stock Information

Company Name: Capricor Therapeutics Inc.
Stock Symbol: CAPR
Market: NASDAQ
Website: capricor.com

Menu

CAPR CAPR Quote CAPR Short CAPR News CAPR Articles CAPR Message Board
Get CAPR Alerts

News, Short Squeeze, Breakout and More Instantly...

CAPR - Capricor scales up manufacturing capacity for DMD therapy

2024-02-20 13:15:30 ET More on Capricor Therapeutics Seeking Alpha’s Quant Rating on Capricor Therapeutics Historical earnings data for Capricor Therapeutics Financial information for Capricor Therapeutics Read the full article on Seeking Alpha ...

CAPR - Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

-Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024- SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the trea...

CAPR - Caprock Appoints New Chief Financial Officer

Toronto, Ontario--(Newsfile Corp. - February 1, 2024) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce the appointment of Mr. Okunola Joshua Aina as its Chief Financial Officer, effective today. Mr. Aina is a senior finance and accounting professional wh...

CAPR - Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

-Project NextGen Collaboration will Support Capricor’s StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic- SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing tra...

CAPR - Caprock Announces Amendment to Option Agreement

Toronto, Ontario--(Newsfile Corp. - January 22, 2024) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce that it has entered into an amendment to its option agreement dated January 31 st , 2023 (the " Option Agreement ") setting out the terms of an option t...

CAPR - Caprock Makes Second Zinnwaldite Discovery at Ackley - Announces Multiple New High-Grade Lithium Assays

Toronto, Ontario--(Newsfile Corp. - January 17, 2024) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce a second discovery of lithium-bearing zinnwaldite mineralization (" Area 2 ") in addition to the previously discussed Deer Pond Area within the east...

CAPR - Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku-- --HOPE-3 (Cohort A) Enrollment Complete; Topline Data Expected in the Fourth Quarter of 2024; Cohort B Enrollment Initiated-- ...

CAPR - Caprock Confirms Zinnwaldite as the Lithium-Bearing Mineral at Ackley

Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - Caprock Mining Corp. (CSE: CAPR) ( "Caprock" or the "Company" ) is pleased to announce that following a comprehensive analysis by SGS Natural Resources ( "SGS" ) based in Lakefield, Ontario, the lithium-bearing mineral in samples col...

CAPR - Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript

2023-11-14 20:30:05 ET Capricor Therapeutics, Inc. (CAPR) Q3 2023 Results Conference Call November 14, 2023 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Aydin H...

CAPR - Capricor Therapeutics GAAP EPS of -$0.25 beats by $0.05, revenue of $6.19M beats by $3.02M

2023-11-14 16:08:08 ET More on Capricor Therapeutics Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Capricor Therapeutics Q3 2023 Earnings Preview Capricor Therapeutics Q3 2...

Previous 10 Next 10